Overcoming Barriers: Improving Access for Rare Disease Patients through Cross-Border Healthcare

EUCOPE's Sounds of Science

EUCOPE

Science, Life Sciences

0 • 0 Ratings

🗓️ 6 June 2022

⏱️ 30 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

SOUNDS OF SCIENCE - EPISODE 6

The Cross-Border Healthcare Directive (Directive 2011/24/EU) marked a milestone for European patients. It created a legal framework for the patient’s right to seek healthcare in another Member State and to be reimbursed. It also provided a legal basis for enhanced European cooperation in key areas of healthcare – including quality and safety, Health Technology Assessment and eHealth, and rare diseases.

On May 12, the Commission published their long awaited evaluation of the Cross-Border Healthcare Directive. The report outlines several areas for improvement, but does not call for a reopening of the Directive, which would be a political decision as well.

As more Advanced Therapy Medicinal Products (ATMPs) have become available across Member States, it is still unclear how the cross-border healthcare framework will make access to such transformative treatment abroad more accessible. In this podcast, we’re addressing a number of complex issues with a lot of terminology so today we’ll be discussing the CBH in a holistic manner. The speakers will be able to clarify between the concept of CBH and the Directive itself.

Joining us on this podcast are:

Thomas Bols, Head of Government Affairs and Patient Engagement, PTC Therapeutics
Victor Maertens, Government Affairs Manager, EUCOPE

------------------------------------------------------

The European Alliance for Transformative Therapies (TRANSFORM) is a multi-stakeholder Alliance that connects Members of the European Parliament (MEPs) and policy-makers with patient groups, medical experts and associations, scientists, researchers, industry actors, networks and other relevant stakeholders. More info at https://transformalliance.eu/

EUCOPE's Position Paper - Cross Border Healthcare for Patients: What can be done?

Learn more about EUCOPE at www.eucope.org

Transcript

Click on a timestamp to play from that location

0:00.0	Hello and welcome to Sounds of Science, a series of podcasts hosted by
0:09.0	Yukope, the European Trade Body representing small and mid-sized companies active in health technologies.
0:14.0	My name is Dante Diulio and I'm the Communications and Business Development Manager at
0:18.0	Yukope and your host on today's pod. Before moving forward, I'd like to kindly ask you to click on the subscribe button below
0:24.4	and kindly follow us on Twitter and LinkedIn to stay up to date on all of the latest news and initiatives
0:29.5	within the world of European life sciences.
0:42.0	The Cross-Border Healthcare Directive marked a milestone for European patients.
0:46.0	It created a legal framework for the patient's right to seek health care in another member state and to be reimbursed. On May 12th, the commission published a longer-weighted evaluation
0:50.9	of the cross-border health healthcare directive. The report outlined several areas
0:54.9	for improvement, but does not call for a reopening of the directive, which would be a political
0:58.8	decision. As more ATMPs become available across Europe, it is still unclear how the cross-border
1:04.6	healthcare framework will make access to such transformative treatment abroad more accessible. To help
1:10.2	reflect on the European Commission's report and discuss the challenges and opportunities
1:13.9	available to prove access for rare disease patients through cross-border healthcare, we're
1:18.6	joined by a member of PTC Therapeutics, represented here by Thomas Bowles, Head of Government
1:23.0	Affairs, and patient engagement, as well as Eucope's very own government affairs manager, Victor,
1:28.3	Martin's.
1:29.3	Welcome, Thomas.
1:30.3	Thanks for joining me today.
1:31.3	Thank you.
1:32.3	Thank you for having me.
1:33.3	And welcome, Victor.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from EUCOPE, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of EUCOPE and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.